Prospective evaluation of first-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicenter academic phase II study in Caucasian patients (FIELT)

Jacques de Grève*, Jan van Meerbeeck, Johan F. Vansteenkiste, Lore Decoster, Anne Pascale Meert, Peter Vuylsteke, Christian Focan, Jean Luc Canon, Yves Humblet, Guy Berchem, Benoit Colinet, Danny Galdermans, Lionel Bosquée, Joanna Vermeij, Alex Dewaele, Caroline Geers, Denis Schallier, Erik Teugels

*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

16 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Prospective evaluation of first-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicenter academic phase II study in Caucasian patients (FIELT)'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science